Efficacy and safety of Qingwei Zhitong pellets-containing quadruple therapy for eradication: a prospective, single-center, randomized trial.
Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: OBJECTIVE: ) infection. METHODS: This single-center, randomized controlled clinical trial enrolled 333 patients, who were divided into either the QZQT group (QZ pellets, 3.2 g, three times daily; rabeprazole, 10 mg, twice daily; amoxicillin 1000 mg, twice daily; clarithromycin, 500 mg, twice daily) or the BQT group (bismuth potassium citrate, 1000 mg, three times daily; rabeprazole, 10 mg, twice daily; amoxicillin, 1000 mg, twice daily; clarithromycin, 500 mg, twice daily) for 14 d. The 13C-urea breath test assessed eradication success at least four weeks after treatment. The primary outcome focused on the eradication rate, with secondary outcomes including safety and patient compliance. RESULTS: 0.001). CONCLUSION: infection.
Source: PubMed
Authors: Cheng Jianping, Fan Chanjuan, Zhai Lili, Wang Hui, Xie Dongling, Cai Yong, L I Zhen, Huang Kun, Bai Qixuan
Institution: Aviation General Hospital
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4408956641